Johnson & Johnson stock: 26 Impella presentations at TCT 2026
Published on 10/30/2026 at 16:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSImpella evidence takes center stage
- Johnson & Johnson will present new Impella research at the TCT 2026 conference in San Diego.
- The program covers high-risk coronary intervention, cardiogenic shock, myocardial recovery and renal perfusion.
- A health-economic model will compare Impella with intra-aortic balloon pumps in selected heart-failure procedures.
Johnson & Johnson announced on Thursday, October 29, that 26 presentations on Impella heart pumps are scheduled for the Transcatheter Cardiovascular Therapeutics conference in San Diego from Saturday, October 31, through Tuesday, November 3. The announcement adds a fresh MedTech focus for investors ahead of the meeting.
The company said the research covers high-risk percutaneous coronary intervention, cardiogenic shock, myocardial recovery, renal perfusion, physiologic risk and next-generation technology. Johnson & Johnson also described three analyses of contemporary US and European experience with Impella-supported high-risk intervention, positioning the work in the context of the CHIP-BCIS3 study results.
New evidence across heart recovery
Among the featured work is a health-economic model that projects lower lifetime healthcare costs and greater quality-adjusted survival with Impella than with an intra-aortic balloon pump in heart-failure patients undergoing high-risk intervention. Other presentations address real-world protected PCI, infarct-size reduction, early mortality and patient characteristics in a high-risk PCI cohort.
The company said its Impella evidence base spans more than two decades and includes randomized trials, prospective studies, registries and real-world clinical practice. It also plans an evening scientific program on Sunday, November 1, and a World Connect Symposium on Monday, November 2, focused on heart recovery and Impella evidence. These are scheduled events rather than reported clinical outcomes.
Johnson & Johnson said the presentation program is intended to advance clinical evidence and inform practice. The release includes forward-looking statements, so the planned research should not be treated as proof of future commercial or clinical performance.
The real-time quote of Johnson & Johnson stock was 247.18 euros on Lang & Schwarz at 4:36 p.m. CET on Friday, October 30, 2026.
Johnson & Johnson stock facts
- Company: Johnson & Johnson
- ISIN: US4781601046
- Ticker: JNJ
- Lang & Schwarz quote: 247.18 euros on Friday, October 30, 2026, at 4:36 p.m. CET
The broader US market backdrop is covered in the current market reports.
